DEF 14A: Onconetix Seeks Stockholder Approval for Key Proposals Including Reverse Stock Split and Equity Incentive Plan Amendment

Onconetix is seeking stockholder approval for several proposals at its upcoming annual meeting, including the election of directors, an amendment to its equity incentive plan, and a reverse stock split.

Summary

• Onconetix, Inc. is holding its annual meeting on September 5, 2024, to vote on several key proposals.
• The proposals include the election of Timothy Ramdeen and Ajit Singh as Class III directors, amendments to the 2022 Equity Incentive Plan to increase the number of shares available by 54,850,000, and a reverse stock split of common stock at a ratio between 1-for-30 and 1-for-60.
• Stockholders will also vote on approving the issuance of up to 5,709,935 shares of Common Stock upon conversion of the Company's Series A Preferred Stock.
• Additionally, the meeting will address the approval of the issuance of 269,672,900 shares of Common Stock upon conversion of the Series B Preferred Stock, the issuance of shares in a $5 million private placement (PMX Financing), and the assumption and conversion of Proteomedix stock options.
• The final proposal involves ratifying the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Onconetix Board unanimously recommends that stockholders vote FOR each of the proposals.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive aspects such as the potential for Proclarix and the board's recommendations, the financial risks and need for additional capital raise concerns.

Positives

• The proposed reverse stock split aims to increase the per-share trading price of Onconetix's common stock, potentially attracting a broader range of investors.
• Increasing the number of shares available under the 2022 Equity Incentive Plan will help Onconetix attract and retain key employees, directors, and consultants.
• The PMX Transaction and related financing are expected to provide Onconetix with additional capital and expertise in the men's health and oncology space.
• The appointment of EisnerAmper LLP as the Company's independent registered public accounting firm provides stability and continuity in the Company's financial oversight.

Negatives

• The reverse stock split may decrease the liquidity of Onconetix's common stock.
• The issuance or conversion of securities would result in significant dilution in the equity interest of existing shareholders.
• The company shareholders may not realize a benefit from the ENTADFI or Proteomedix acquisitions commensurate with the ownership dilution they have experienced in connection with the transactions.
• There is substantial doubt about our ability to continue as a going concern, and we will require substantial additional funding to finance our long-term operations.

Risks

• The company shareholders may not realize a benefit from the ENTADFI or Proteomedix acquisitions commensurate with the ownership dilution they have experienced in connection with the transactions.
• The issuance or conversion of securities would result in significant dilution in the equity interest of existing shareholders and adversely affect the marketplace of the securities.
• There is substantial doubt about our ability to continue as a going concern, and we will require substantial additional funding to finance our long-term operations.
• If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate certain of our products or other operations.
• We may not be able to successfully grow sales of ENTADFI in the U.S. market and Proclarix in the European markets or, if authorized, grow sales of either in any other market.

Future Outlook

Onconetix expects to generate revenue from sales of Proclarix by 2025 and anticipates that its expenses will increase substantially in connection with its ongoing activities.

Management Comments

• The Onconetix Board has unanimously determined and resolved that the proposals are advisable and fair to, and in the best interests of, Onconetix and its stockholders, and has approved the Reverse Stock Split Amendment, subject to stockholder approval.
• Accordingly, the Onconetix Board unanimously recommends that Onconetix stockholders vote FOR each of the foregoing proposals.

Industry Context

The announcement reflects Onconetix's strategic shift towards men's health and oncology, aligning with broader industry trends in personalized medicine and diagnostic testing.

Comparison to Industry Standards

• The guidelines of the European Association of Urology (EAU) and of the American Urological Association/Society of Urologic Oncology (AUA/SUO) both recommend the use of blood-based biomarker tests, such as Proclarix, to aid in the early detection and evaluation of prostate cancer.
• Proclarix can be performed in any laboratory using standard equipment.
• In 2023, Proteomedix had revenues of $67,380 from sales of Proclarix, compared to $79,085 in 2022.

Legal Proceedings

• WraSer has recently filed a plan of reorganization that indicates it may seek damages from us due to the termination of the APA and MSA.

Related Party Transactions

• On January 23, 2024, the Company issued the Altos Debenture in the principal sum of $5.0 million, in connection with a Subscription Agreement, to Altos Venture AG, a stockholder of the Company and related party.

Stakeholder Impact

• Approval of the proposals will impact shareholders through potential dilution and changes in stock price.
• Employees may be affected by changes in the equity incentive plan and potential restructuring activities.
• Customers and suppliers may be impacted by changes in the company's business strategy and operations.

Next Steps

• Solicit proxies from stockholders for the Annual Meeting.
• File a registration statement on Form S-1 or Form S-4 in connection with the registration under the Securities Act of 1933, as amended (the Securities Act), of the issuance of Onconetix Securities to be issued under the Share Exchange Agreement and prepare a Proxy Statement for the purpose of soliciting proxies from Onconetix stockholders for the matters to be acted upon at the Annual Meeting.
• Ensure that the application for Onconetixs change of control (Nasdaq Change of Control Application) is filed with The Nasdaq Stock Market LLC (Nasdaq) and to respond to any questions from Nasdaq with respect to the Nasdaq Change of Control Application promptly following receipt of such questions, but in no event later than ten (10) business days following receipt of such questions.

Key Dates

Keywords

Onconetix, stockholders, reverse stock split, equity incentive plan, directors, preferred stock, PMX Issuance, Warrant Inducement, EisnerAmper, annual meeting, Proteomedix, PMX Financing, Series B Preferred Stock, Series A Preferred Stock, ENTADFI